Optimizing Treatment for Metastatic Castration-Sensitive Prostate Cancer: Expert Perspectives

Key opinion leaders in the field of prostate cancer management consider optimal molecular testing practices in a patient with metastatic hormone-sensitive disease.

Panelists reflect on molecular markers and other clinical factors that aid in the selection of best therapy for a patient with metastatic hormone-sensitive prostate cancer.

Focused discussion on the respective roles of doublet and triplet regimens in patients newly diagnosed with metastatic hormone-sensitive prostate cancer.

After nuancing quality of life data with chemotherapy in metastatic hormone-sensitive prostate cancer, panelists consider the value of multidisciplinary care.

Shared insight on strategies to monitor patient response to therapy and select second-line treatment when hormone-sensitive prostate cancer progresses.

Centering focus on a second clinical scenario of metastatic hormone-sensitive prostate cancer, key opinion leaders identify treatment options based on variations in presentation.

In a third clinical scenario of metastatic hormone-sensitive prostate cancer, panelists discuss oligometastatic disease, radiation therapy, and the potential role for PSMA-PET scans.

Expert panelists consider the possibility of taking a break from treatment given a patient’s response to therapy along with other unique management strategies in the setting of metastatic hormone-sensitive prostate cancer.

Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.

Experts review current treatments for metastatic castration-sensitive prostate cancer, centering their discussion around a patient case.